These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17932167)

  • 1. Let cost effectiveness models be open to scrutiny.
    Poole C; Agrawal S; Currie CJ
    BMJ; 2007 Oct; 335(7623):735. PubMed ID: 17932167
    [No Abstract]   [Full Text] [Related]  

  • 2. Disinvestment from low value clinical interventions: NICEly done?
    Garner S; Littlejohns P
    BMJ; 2011 Jul; 343():d4519. PubMed ID: 21795239
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation: an introduction.
    Raftery J
    BMJ; 1998 Mar; 316(7136):1013-4. PubMed ID: 9550969
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical value of computed tomography scanning and magnetic resonance imaging: studies in the United Kingdom.
    Dixon AK
    Acad Radiol; 1996 Apr; 3 Suppl 1():S49-50. PubMed ID: 8796511
    [No Abstract]   [Full Text] [Related]  

  • 5. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 6. Searching for a threshold - Not so NICE..
    Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
    J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
    [No Abstract]   [Full Text] [Related]  

  • 7. NICE and new: appraising innovation.
    Ferner RE; Hughes DA; Aronson JK
    BMJ; 2010 Jan; 340():b5493. PubMed ID: 20051468
    [No Abstract]   [Full Text] [Related]  

  • 8. The iterative use of economic evaluation as part of the process of health technology assessment.
    Sculpher M; Drummond M; Buxton M
    J Health Serv Res Policy; 1997 Jan; 2(1):26-30. PubMed ID: 10180650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 10. Handling uncertainty in economic evaluations of healthcare interventions.
    Briggs AH; Gray AM
    BMJ; 1999 Sep; 319(7210):635-8. PubMed ID: 10473486
    [No Abstract]   [Full Text] [Related]  

  • 11. Investment. To replace or not to replace.
    Moore A
    Health Serv J; 2013 Nov; 123(6376):20-1. PubMed ID: 24416974
    [No Abstract]   [Full Text] [Related]  

  • 12. A little learning: reflections on 10 years of NICE technology appraisals.
    Longson CM
    Health Econ; 2012 Jan; 21(1):30-2. PubMed ID: 22147626
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost effectiveness of renal provision in the UK.
    Haycox A; Jones D
    J Manag Med; 1996; 10(1):6-15. PubMed ID: 10162928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
    Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
    Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considering the value associated with innovation in health technology appraisal decisions (deliberations): a NICE thing to do?
    Green C
    Appl Health Econ Health Policy; 2010; 8(1):1-5. PubMed ID: 20038189
    [No Abstract]   [Full Text] [Related]  

  • 16. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE's citizen's council: what do we ask them, and how?
    Dolan P; Tsuchiya A; Wailoo A
    Lancet; 2003 Sep; 362(9387):918-9. PubMed ID: 13678989
    [No Abstract]   [Full Text] [Related]  

  • 20. Health technology assessment in the United Kingdom.
    Akehurst R
    Value Health; 2010 Jun; 13 Suppl 1():S4-5. PubMed ID: 20618794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.